A Global Inventory of Alternative Medical Waste Treatment Technologies
This summary highlights the experiences, results and actions from
the implementation of the Rapid Assessment Tool for Sexual and
The tool – developed by IPPF, UNFPA, WHO, UNAIDS, GNP+, ICW and Young Positives in
2009 – supports national assessments of the bi-directional linkages
between sexu...al and reproductive health (SRH) and HIV at the policy,
systems and services levels. Each country that has rolled out the
tool has gathered and generated information that will help to
determine priorities and shape national plans and frameworks for
scaling up and intensifying linkages. Country experiences and best
practices will also inform regional and global agendas.
more
This is one of seven Medical Peace Work courses.
POST TRAINING FOLLOW-UP TOOL
This manual is designed to help you:
Understand what schizophrenia is and the problems it causes - this is covered in Section A
Learn how to help people schizophrenia and their families through CBR - this is covered in Section B
Know how you will be supported to deliver CBR - this is ...covered in Section C
Throughout the manual you will follow the experiences of Yosef and Sara, people with schizophrenia, and their families. Yosef and Sara are not real people, but their stories include situations and events that real people with schizophrenia have experienced.
more
Program Implementation Manual (PIM)
The Save One Million Lives Program for Results (SOML PforR) is a Federal Government of Nigeria maternal and child health program, supported by the World Bank, which provides incentives based on achievement of results (health outcomes) and helps to drive insti...tutional processes needed to achieve these results.
This Program Implementation Manual provides a description of the program and operational guidelines for effective implementation. The Manual contains guidelines and procedures relating to disbursements and fund flows, institutional arrangements, financial management as well as monitoring and evaluation, while providing clear definition of the roles and responsibilities of all stakeholders.
more
Findings on maternal and child health in Nepal, Mozambique and
Rwanda, and neglected tropical diseases in Cambodia and Sierra Leone | This report synthesises findings from five country case studies from the health dimension of this project, which focus on maternal and child health (MCH) (Mozambique...,Nepal, Rwanda) and neglected tropical diseases (NTDs)(Cambodia, Sierra Leone). MCH was selected given its centrality in two of the Millennium Development Goals (MDGs) and its ability to act as a proxy for strengthened health systems. NTDs, while until recently relatively neglected in global policy debates, are now attracting more interest, not least because they are viewed as diseases of the poor whose treatment could positively impact on most of the other MDGs.
more
Regulation of the Minister of Health of the Republic of Indonesia Number 74 Year 2014: Guidelines for Implementation of Hiv Counseling and Test
Reference Manual for Programme Managers on Accreditation Process
Abridge Course for Physicians. Facilitator guide for modules, Integrated Management of Neonatal and Childhood Illness (IMNCI)
Rethinking Health with Covid-19 Lessons and Challenges
Este e-book que integra estratégias de três Projetos PROADISUS (Lean nas Emergências, Reab pós-COVID-19 e Cuidados Paliativos) e expõe temas relevantes, relacionados à necessidade de retorno seguro de atividades hospitalares, em paralelo ...à crise que a pandemia ainda impõe a todos os serviços de saúde. Abordaremos estratégias para a reativação ou retomada de serviços hospitalares em paralelo à presença do SARS-CoV-2.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more